Branded medicines levy cut under statutory scheme The Department of Health and Social Care said that the new 16.5% levy, a fall from the previous year’s 24.3%, will take effect from 1 July 2026.…
Advanced therapy medicinal products: a tsunami in clinical medicine Advanced therapy medicinal products offer life-changing benefits for patients with little to no alternative treatments, but realising their full potential requires action across the entire healthcare system.…
Government medicines manufacturing training scheme used by more than 2,000 people so far The RESILIENCE programme has been developed to provide training for people in the medicines manufacturing sector.…
Health news round up: AMR, pain and genitourinary cancers A weekly summary of important developments in pharmacy and health news that you may have missed.…
Why the UK must put medicines at the forefront of a new EU relationship Why the UK’s priorities need to change in terms of medicines regulation, which will ultimately determine whether future patients will benefit from affordable medicines supply.…
Regulators set out support for in-orbit pharmaceutical manufacturing In a joint statement, UK regulators said that the production of materials and products in space have the potential to offer higher quality medicines compared with those made on Earth.…
Medicines rebate rate to fall by more than one-third in 2026 The Department of Health and Social Care said the decrease in the payment rate for newer medicines was partly influenced by falling costs, such as drugs going off-patent.…
Beyond GLP-1: the next wave of weight-loss medication innovation From agonists and antagonists to ultrasound therapy, an in-depth look at the drug development pipeline has highlighted several promising new potential weight-loss medicines.…
Government and APBI fail to reach agreement on cost of branded medicines The levy paid to the government on the sales of branded medicines to the NHS is higher than the rates paid in other countries, such as Ireland, Belgium, Germany and France.…
Medicines derived from UK blood plasma distributed to NHS hospitals for ‘first time in a generation’ More than 250,000 litres of plasma from UK donors have been sent to human protein product manufacturer Octapharma to produce NHS medicines for the first time since a 1998 ban.…
